Article Details

Novartis iptacopan beats AstraZeneca's Soliris/Ultomiris to treat rare blood disorder in trial

Retrieved on: 2022-10-24 10:04:34

Tags for this article:

Click the tags to see associated articles and topics

Novartis iptacopan beats AstraZeneca's Soliris/Ultomiris to treat rare blood disorder in trial. View article details on HISWAI: https://seekingalpha.com/news/3893973-novartis-iptacopan-beats-astrazenecas-solirisultomiris-to-treat-rare-blood-disorder-in-trial%3Fsource%3Dcontent_type%253Areact%257Cfirst_level_url%253Amarket-news%257Csection_asset%253Amain

Excerpt

Novartis (NVS) said its oral drug iptacopan met the two main goal of a phase 3 trial by showing superiority over AstraZeneca's (AZN) Soliris ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up